GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Within Neuromodulation, Boston Scientific’s pain business is consistently gaining traction, banking on strength in Spinal cord stimulation (SCS), driven by its innovative Alpha portfolio with ...
Brinker International, Business First Bancshares, AZEK, Celestica and Boston Scientific have been highlighted in this Screen of The Week article. We recently published a list of the 10 Best ...
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...
Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a ...